Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
|Articles|October 21, 2021
ANGUS to Expand U.S. Manufacturing Capacity for Tromethamine Buffers
Author(s)BioPharm International Editors
ANGUS’ planned expansion will double its tromethamine buffer production capacity.
Advertisement
ANGUS Chemical Company, a manufacturer of unique nitroalkane chemistries, announced plans to expand United States production capacity for its portfolio of Tris Amino (tromethamine) buffers on Oct. 14, 2021. The planned expansion features the addition of a fourth dedicated manufacturing line at ANGUS' existing Sterlington, La., facility, which will approximately double the company’s production capacity.
Tromethamine buffers are used in various manufacturing capacities, such as bioprocessing and diagnostics manufacturing or the synthesis of surface-active agents and pharmaceuticals, among others. This expansion is the latest in a series of moves made by ANGUS to increase tromethamine buffer production capacity; from 2016 to 2021, the company doubled its tromethamine buffer production capacity.
“This is a significant investment that highlights our commitment to continuously expanding our asset base and global manufacturing capabilities to support fast-growing demand for [tromethamine] buffers across life sciences, personal care and industrial markets,” said David Neuberger, ANGUS president and CEO, in a company press release. “It not only supports the pursuit of our vision to position ANGUS as a leading global supplier of essential life sciences ingredients, but also further enhances the supply chain continuity and security of supply we provide to our customers for this essential chemistry.”
Currently, the company has facilities in Chicago, Ill; Paris, France; São Paulo, Brazil; Singapore; Shanghai, China; and Mumbai, India. It is headquartered in Buffalo Grove, Ill.
Source:
Advertisement
Related to this article
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5